286 research outputs found
Study of decays to the final state and evidence for the decay
A study of decays is performed for the first time
using data corresponding to an integrated luminosity of 3.0
collected by the LHCb experiment in collisions at centre-of-mass energies
of and TeV. Evidence for the decay
is reported with a significance of 4.0 standard deviations, resulting in the
measurement of
to
be .
Here denotes a branching fraction while and
are the production cross-sections for and mesons.
An indication of weak annihilation is found for the region
, with a significance of
2.4 standard deviations.Comment: All figures and tables, along with any supplementary material and
additional information, are available at
https://lhcbproject.web.cern.ch/lhcbproject/Publications/LHCbProjectPublic/LHCb-PAPER-2016-022.html,
link to supplemental material inserted in the reference
Measurement of the CKM angle γ from a combination of B±→Dh± analyses
A combination of three LHCb measurements of the CKM angle γ is presented. The decays B±→D K± and
B±→Dπ± are used, where D denotes an admixture of D0 and D0 mesons, decaying into K+K−, π+π−, K±π∓, K±π∓π±π∓, K0Sπ+π−, or K0S K+K− final states. All measurements use a dataset corresponding to 1.0 fb−1 of integrated luminosity. Combining results from B±→D K± decays alone a best-fit value of
γ =72.0◦ is found, and confidence intervals are set
γ ∈ [56.4,86.7]◦ at 68% CL,
γ ∈ [42.6,99.6]◦ at 95% CL.
The best-fit value of γ found from a combination of results from B±→Dπ± decays alone, is γ =18.9◦,
and the confidence intervals
γ ∈ [7.4,99.2]◦ ∪ [167.9,176.4]◦ at 68% CL
are set, without constraint at 95% CL. The combination of results from B± → D K± and B± → Dπ±
decays gives a best-fit value of γ =72.6◦ and the confidence intervals
γ ∈ [55.4,82.3]◦ at 68% CL,
γ ∈ [40.2,92.7]◦ at 95% CL
are set. All values are expressed modulo 180◦, and are obtained taking into account the effect of D0–D0
mixing
Functional Roles for CSPG4/NG2 in Chondrosarcoma
CSPG4/NG2 is a multifunctional transmembrane protein with limited distribution in adult tissues including articular cartilage. The purpose of this study was to investigate the possible roles of CSPG4/NG2 in chondrosarcomas and to establish whether this molecule may have potential for targeted therapy. Stable knock‐down of CSPG4/NG2 in the JJ012 chondrosarcoma cell line by shRNA resulted in decreased cell proliferation and migration as well as a decrease in gene expression of the MMP (matrix metalloproteinase) 3 protease and ADAMTS4 (aggrecanase). Chondrosarcoma cells in which CSPG4/NG2 was knocked down were more sensitive to doxorubicin than wild‐type cells. The results indicate that CSPG4/NG2 has roles in regulating chondrosarcoma cell function in relation to growth, spread and resistance to chemotherapy and that anti‐CSPG4/NG2 therapies may have potential in the treatment of surgically unresectable chondrosarcoma
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the most common genetic alterations in intrahepatic cholangiocarcinoma (IHCC), a deadly liver cancer1, 2, 3, 4, 5. Mutant IDH proteins in IHCC and other malignancies acquire an abnormal enzymatic activity allowing them to convert α-ketoglutarate (αKG) to 2-hydroxyglutarate (2HG), which inhibits the activity of multiple αKG-dependent dioxygenases, and results in alterations in cell differentiation, survival, and extracellular matrix maturation6, 7, 8, 9, 10. However, the molecular pathways by which IDH mutations lead to tumour formation remain unclear. Here we show that mutant IDH blocks liver progenitor cells from undergoing hepatocyte differentiation through the production of 2HG and suppression of HNF-4α, a master regulator of hepatocyte identity and quiescence. Correspondingly, genetically engineered mouse models expressing mutant IDH in the adult liver show an aberrant response to hepatic injury, characterized by HNF-4α silencing, impaired hepatocyte differentiation, and markedly elevated levels of cell proliferation. Moreover, IDH and Kras mutations, genetic alterations that co-exist in a subset of human IHCCs4, 5, cooperate to drive the expansion of liver progenitor cells, development of premalignant biliary lesions, and progression to metastatic IHCC. These studies provide a functional link between IDH mutations, hepatic cell fate, and IHCC pathogenesis, and present a novel genetically engineered mouse model of IDH-driven malignancy
Gauge bosons at zero and finite temperature
Gauge theories of the Yang-Mills type are the single most important building
block of the standard model and beyond. Since Yang-Mills theories are gauge
theories their elementary particles, the gauge bosons, cannot be described
without fixing a gauge. Beyond perturbation theory, gauge-fixing in non-Abelian
gauge theories is obstructed by the Gribov-Singer ambiguity. The construction
and implementation of a method-independent gauge-fixing prescription to resolve
this ambiguity is the most important step to describe gauge bosons beyond
perturbation theory. Proposals for such a procedure, generalizing the
perturbative Landau gauge, are described here. Their implementation are
discussed for two example methods, lattice gauge theory and the quantum
equations of motion. The most direct access to the properties of the gauge
bosons is provided by their correlation functions. The corresponding two- and
three-point correlation functions are presented at all energy scales. These
give access to the properties of the gauge bosons, like their absence from the
asymptotic physical state space, the absence of an on-shell mass pole,
particle-like properties at high energies, and their running couplings.
Furthermore, auxiliary degrees of freedom are introduced during gauge-fixing,
and their properties are discussed as well. These results are presented for
two, three, and four dimensions, and for various gauge algebras. Finally, the
modifications of the properties of gauge bosons at finite temperature are
presented. Evidence is provided that these reflect the phase structure of
Yang-Mills theory. However, it is found that the phase transition is not
deconfining the gauge bosons, although the bulk thermodynamical behavior is of
a Stefan-Boltzmann type. The resolution of this apparent contradiction is also
presented. This resolution also provides an explicit and constructive solution
to the Linde problem.Comment: v2: 153 pages, 45 figures, revised, updated, and extended version
submitted on invitation to Physics Reports; v3: Intermediate update, 152
pages, 45 figures, minor errors corrected, reference list extended; v3 minor
typographical changes and corrections, added references, version to appear in
Physics Report
Oxidative Stress in Cancer
Contingent upon concentration, reactive oxygen species (ROS) influence cancer evolution in apparently contradictory ways, either initiating/stimulating tumorigenesis and supporting transformation/proliferation of cancer cells or causing cell death. To accommodate high ROS levels, tumor cells modify sulfur-based metabolism, NADPH generation, and the activity of antioxidant transcription factors. During initiation, genetic changes enable cell survival under high ROS levels by activating antioxidant transcription factors or increasing NADPH via the pentose phosphate pathway (PPP). During progression and metastasis, tumor cells adapt to oxidative stress by increasing NADPH in various ways, including activation of AMPK, the PPP, and reductive glutamine and folate metabolism
Observation of the Annihilation Decay Mode B0 →k+K-
A search for the B0→K+K- decay is performed using pp-collision data collected by LHCb. The data set corresponds to integrated luminosities of 1.0 and 2.0 fb-1 at center-of-mass energies of 7 and 8 TeV, respectively. This decay is observed for the first time, with a significance of more than 5 standard deviations. The analysis also results in an improved measurement of the branching fraction for the Bs0→π+π- decay. The measured branching fractions are B(B0→K+K-)=(7.80±1.27±0.81±0.21)×10-8 and B(Bs0→π+π-)=(6.91±0.54±0.63±0.19±0.40)×10-7. The first uncertainty is statistical, the second is systematic, the third is due to the uncertainty on the B0→K+π- branching fraction used as a normalization. For the Bs0 mode, the fourth accounts for the uncertainty on the ratio of the probabilities for b quarks to hadronize into Bs0 and B0 mesons
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM−/− patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors
- …